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Abstract
Background: Radiosynovectomy is a type of radiotherapy used to relieve pain and inflammation
from rheumatoid arthritis. In this study, 188-Rhenium (188Re) colloids were characterized by
physical and biological methodologies. This was used to assess which parameters of the kit
formulation would be the basis in the development of a more effective radiopharmaceutical for
synovectomy. Intraarticular injection in knees of rabbits assessed cavity leakage of activity.
Methods: The physical characteristics of tin (Sn) and sulphur (S) colloids were determined to
assess the formulation with suitable properties. Particles were grouped in three ranges for
analyzing their distribution according to their number, volume and surface. The ideal particle size
range was considered to be from 2 to 10 microns. Membrane filtration and laser diffraction
characterization methodologies were used.
Results: While membrane filtration could give misleading data, laser diffraction proportions more
reliable results. The Sn colloid showed a better distribution of particle volume and surface than S
colloid, in the 2 to 10 microns range. The 188Re-Sn colloid was obtained with a radiochemical purity
higher than 95% after 30 minutes of autoclaving. While Sn colloid kit stability was verified for 60
days, the 188Re-Sn preparation was stable in the first 24 hrs. No significant intrabatch variability (n
= 3) was detected. Biodistribution and scintigraphic studies in rabbits after intraarticular injection
showed relevant activity only in knee, being 90% at 48 hours.
Conclusion: The 188Re-Sn colloid is easy to prepare, is stable for 24 hours and shows minimal
cavity leakage after intraarticular injection into rabbit knees, suggesting this radiotherapeutical
agent has suitable physical properties for evaluation for joint treatment in humans.
Background
Radiosynovectomy is a radiotherapy, which has been used
for more than 40 years to relieve pain and inflammation
from rheumatoid arthritis (RA). It was developed as an al-
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ternative to surgical synovectomy [1–3]. The procedure
consists in the injection of a beta-emitting radionuclide
into the joint capsule [4,5], where it remains in contact
with the synovial membrane or synovium. The intraartic-
ular-administered radiopharmaceutical is then phagocyt-
ed by the lining cells, which are on the synovial surface.
While the radionuclide is decaying the absorbed dose is
being given to the synovium.
188Rhenium is an attractive radionuclide for radiosyn-
ovectomy because of its suitable chemistry, t1/2 = 16.9
hours and average beta energy of 776 keV (Emax = 2.11
MeV, 79%). These properties enable knee treatment due
to its maximal tissue penetration of 11 mm, and its mean
range of 3.8 mm [6,8]. 188Re decays to the stable 188Os,
with a gamma ray emission of 155 KeV (15%) that is suit-
able for image acquisition. This fact allows target uptake
evaluation, as well as the estimation of the absorbed radi-
ation dose. Besides this, rhenium-188 is readily available
on routine bases from the tungsten-188/rhenium-188
generator system [9,10], which has a useful shelf-life of
several months.
The ideal radiopharmaceutical radiolabeled with 188Re
for radiosynovectomy should meet the following require-
ments:
a) 188Rhenium should be attached to a particle that is suf-
ficiently small to be phagocytized, but not so small that it
might leak from the joint before being phagocytized; the
appropriate size range is usually considered to be from 2
to 10 microns;
b) the binding between the radionuclide and the particle
should be irreversible throughout the course of the radio-
therapy, which, in turn, is determined by the physical
half-life of the radionuclide;
c) the radiolabeled particles should be distributed homo-
geneously in the joint without initiating an inflammatory
response.
Taking into account a previous study [11], which showed
that colloidal preparations are the ones that best fulfil
these requirements, the 188Re-Sn and 188 Re-S colloids
were prepared.
The radiocolloid preparations were studied by two meth-
odologies – laser diffraction and membrane filtration – in
order to analyze which physical parameters were more rel-
evant to accomplish the characteristics described above.
In this study, the 188Re colloids were characterized by
physical and biological methodologies to assess which pa-
rameters of the kit formulation enable to achieve a better
radiopharmaceutical for synovectomy. The 188Re-Sn col-
loid was evaluated in preliminary studies by evaluating
capsule leakage by gamma camera imaging after intraar-
ticular administration in rabbit knees.
Methods
Colloids kit composition
The 188Re-Sn colloid was prepared according to the fol-
lowing formulation, modified from that previously re-
ported [11]
10 mg SnCl2.2H2O
0.5 mL HCl 0.1 N
2 mg ascorbic acid
One per cent w/w Tween 80® in experiments where indi-
cated
N2 atmosphere
The 188Re-S colloid kit was prepared with the following
composition [6]:
40 mg Na2S2O3
4.8 mg EDTA disodium salt
0.8 mg KReO4 carrier
1.5 mL 0.9% saline solution
pH was adjusted to 1 with HCl 0.1 N
All reagents used were analytical grade
Preparation and control
Sn colloid preparation was carried out with the following
technique: a kit was heated (by autoclave or water bath)
for preset times (15, 30, 60 or 90 min). Different final vol-
umes were assayed with the addition of 0.9% saline solu-
tion (0, 0.5, 1.0 or 1.5 mL). Two tin kit formulations were
tested: with or without the tensoactive agent (1-% w/w
Tween 80®).
Labeling procedure and quality control
The 188Re were eluted from a 188W/188Re generator (MAP
Technologies, Finland).
The 188Re-Sn colloid was labeled by the addition of 500
Ci (18.5 MBq) of 188ReO4
- to the kit formulation de-
scribed before, then it was autoclaved for 1 h. pH was ad-
justed to 8.0 with a phosphate buffer 0.2 M.BMC Nuclear Medicine 2002, 2 http://www.biomedcentral.com/1471-2385/2/1
Page 3 of 9
(page number not for citation purposes)
Figure 1
Incidence of heating procedure (room temperature, water bath temperature and autoclave) in colloid formation. The particle
distribution of Sn and S colloids was analyzed according to three parameters: (a) number, (b) volume and (c) surface area of the
particles, grouped in three size ranges (lower than 2 microns, between 2 to 10 microns, higher than 10 microns).
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The 188Re-S was labeled by the addition of 500 Ci (18.5
MBq) of 188ReO4
- to the kit formulation described previ-
ously; then it was heated at 100C for 30 min. pH was ad-
justed to 8.0 with a phosphate buffer 0.2 M.
Radiochemical purity was determined by paper chroma-
tography (Whatmann N1) using 0.9% saline solution as
the mobile phase. Radioactivity was measured with a
Nal(Tl) solid scintillation counter of 3  3" (EG&G OR-
TEC Multichannel Analizer).
Physical characterization of the colloids
The physical characterization of Sn and S colloids was
measured adding a similar volume of 0.9% saline solu-
tion to the generator eluate for each kit formulation.
The number, volume and area of the colloid particles were
analyzed with a laser diffraction particle size analyzer
(Particle Size Analyzer Coulter®).
Colloid particle size was also determined by membrane
filtration, with serially connected filters of 1.2, 3 and 5 mi-
crons porous size (Sartorius® AG, cellulose nitrate filter).
The activity retained in each filter and filtrate was meas-
ured in a Capintec Radioisotope Calibrator (CRC-5R, cal-
ibration factor of 496).
Stability studies
In vitro and in vivo stability studies were performed for
the Sn kit
In vitro stability studies
Two batches of the tin colloid kit with or without the ten-
soactive, kept at 2–8C were studied for 60 days. At preset
sampling times of 0, 15, 30, 45 and 60 days, the tin col-
loid was labeled, radiochemical purity was checked and
characterization by laser diffraction and membrane filtra-
tion was done.
In vivo stability studies
Biodistribution in New Zealand adult rabbits (4-kg
weight) were performed. The animals were sacrificed with
an overdose of thiopental sodium after 48 hrs of intraar-
ticular administration of 188Re-Sn colloid (500 Ci/mL,
18.5 MBq/mL). Articulation, liver, spleen, lungs, stomach,
intestines, kidney, muscle, blood and urine samples were
collected and radioactivity was measured in a NaI(Tl)
scintillation counter (Ortec®), with a 3  3" crystal.
This study was carried out at three times: 0, 30 and 60 days
after batch preparation of the tin kit.
Intrabatch variability
Three batches of the tin kit were prepared at the same
time, and physical parameters were determined as de-
Figure 2
Labeled 188Re-Sn colloid vs. reaction time (minutes).
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scribed above, immediately after preparation and seven
days afterwards.
Scintigraphic studies
The New Zealand rabbits were anesthetized by intramus-
cular administration of 50 mg/kg ketamine and 10 mg/kg
of xilazine. Scintigrafic images were acquired with a Shopy
Camera DSX CP, with medium energy collimator, at 0, 24
and 48 hours after intraarticular administration of the ra-
diopharmaceutical.
Results
Kit formulation
The particle distribution of Sn and S colloids was analyzed
according to three parameters: number, volume and sur-
face area of the particles. For this purpose particle size
were grouped in three ranges (lower than 2 microns, be-
tween 2 to 10 microns, higher than 10 microns), as is
shown in Figure 1. The incidence of heating procedure
(room temperature, water bath temperature and auto-
clave) in colloid formation is also shown. The number of
particles of the two colloids did not differ (Figure 1a). The
Sn colloid showed a better particle distribution than the S
colloid, when particle surface area or volumes of both
preparations were considered. Figures 1(b) and 1(c).
Labeling procedure optimization
188Re-Sn colloid was obtained with a radiochemical puri-
ty higher than 90% after autoclaving for 30 min, and high-
er than 95% if heating was maintained for 1 hour (Figure
2). Since electrolytes might destabilize the colloid, the ad-
dition of a saline solution volume was evaluated. When
the ratio (added volume/kit volume) was higher than two,
the percentage of radiolabeled colloid was higher than
90%, as is shown figure 3.
In vitro stability studies
A three-dimensional plot representation (Figure 4) was
chosen to show Sn colloid evolution immediately after
preparation and 60 days afterwards (diameter on the x-ax-
is, particle number on the y-axis and either surface area or
volume on the z-axis). Colloid aging produces an increase
in the volume and surface of the smaller particles, as could
be appreciated when they were shown in the selected
ranges.
Besides this, the stability of a kit that had already been pre-
pared was followed for 24 hours, and no significant
changes were evident during this interval.
Intrabatch variability
The robustness of the product prepared in this manner
was verified, showing minimal variation between 3 batch-
es at t = 0. This behavior was maintained throughout the
first week for all the batches.
Radioactivity vs. particle distribution
The 188Re-Sn colloid was analyzed by membrane filtra-
tion for 8 weeks after kit preparation and the distribution
of the activity was plotted as a function of particle size
grouped in four ranges (< 1.2 microns, 1.2 – 3 microns, 3
– 5 microns and > 5.0 microns), as shown in figure 5. It
can be seen that more than 60% of the activity was found
in particles bigger than 5 microns.
Particle size distribution was not affected by heating 30,
60 or 90 min as shown in figure 6.
Methodologies for physical characterization of colloids
As described above, two methodologies were used to char-
acterize the physical parameters of colloids preparations:
membrane filtration and laser diffraction. Figure 7 com-
pares results for the same colloid formulation studied by
the two techniques. A great difference can be seen between
the results obtained by the two methodologies immedi-
ately after kit preparation between both methodologies.
This observation was in agreement with the fact that tin
colloid variations were significant only during the first
week and were detected by laser diffraction methodology
but not by membrane filtration methodology.
In vivo studies
Figure 8 shows selected organ or tissue activity distribu-
tion, after 48 hours of 188Re-Sn (with or without tensoac-
tive addition) intraarticular administration to New
Zealand rabbits.
The scintigraphic image evidenced relevant activity only
in the knee, and negligible activity in the rest of the organ-
ism. (Figure 9).
Figure 3
Labeled 188Re-Sn colloid vs. the added volume of saline solu-
tion (mL).
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Figure 4
Three-dimensional plot representation of Sn colloid at time = 0 and 60 days afterwards (diameter on the x-axis, particle
number on the y-axis and either surface area or volume on the z-axis).
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Discussion
The physical characteristics of the Sn and S colloids ob-
tained were analyzed to select the formulation, which
showed the best parameters.
It has been well established by other investigators that the
radiopharmaceutical particle size must be small enough
to be phagocyted by the superficial cells of the synovium
but not so small as to facilitate a fast biological clearance
from the articulation [12,13] was taken into account.
Different optimal ranges of particle sizes considered as
ideal for radiosynovectomy have been reported
[4,6,7,12,14,15]. Differences found in the literature are
probably based on the use of different methodologies to
measure particle size. Other parameters were considered
in our study, such as total particle volume or the sum of
different volume sizes grouped in the ranges of interest. In
the same way, another criteria were colloid surface area in
selected ranges.
As radioactivity was deposited as a function of volume or
surface of the particles, methodologies that put this into
evidence and analyzed further modifications of the for-
mulation in the same way should enable to arrive to con-
sistent conclusions. It was found that in the 2–10 microns
range, the Sn colloid attained a greater number, volume
and surface are of particles than those of the S colloid.
Nearly 95% of the S colloid volume belonged to those
particles larger than 100 microns, in spite of the fact that
these were a very small percentage of the whole prepara-
tion. On the other hand, 60% of the Sn colloid volume
was composed of particles with size in the selected range,
while only 5% of the volume of the S autoclaved colloid
gave particles sizes in the same range.
Three-dimensional plot representation turned out to be
an interesting tool to study valuable information about
the behavior of colloids to study particle volume or sur-
face area as a function of number, in a particular range.
Figure 5
Activity distribution (%) vs. time. The 188Re-Sn colloid was
analyzed by membrane filtration for 8 weeks after kit prepa-
ration and activity distribution was grouped in four ranges of
particle size (< 1.2 microns, 1.2 – 3 microns, 3 – 5 microns
and > 5.0 microns).
Figure 6
Activity distribution after heating 30, 60, and 90 minutes
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Methodology evaluation vs. time. Comparison of fractions
over 5 microns obtained with membrane filtration or Coul-
ter methodologies for 8 weeks after kit preparation.
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The correlation of the two colloid characterization meth-
odologies suggested that when a kit was evaluated by
membrane filtration erroneous results might have been
obtained, such as overestimation of particle percentage
due to non-specific retention on the filter. This phenome-
non was observed for those particles larger than 5 mi-
crons, immediately after kit preparation, where the
electrical properties of the colloid were more significant.
Besides that, only laser diffraction methodology provided
a method to evaluate differences due to the aging of kit
formulation during the first week after kit preparation and
during the first 24 hours after similar conditions to those
of labeling of tin colloid. This last observation made it
possible to define a shelf life of 24 hours for the labeled
colloid.
The effect of tensoactive addition was also studied (Tween
80®) in order to facilitate radiopharmaceutical adminis-
tration. It was thought that this addition would not di-
minish colloid stability due to counteract particle
coalition. It is known that small particles will show a grad-
ual increase in size, a phenomenon that is called Ostwald
maturation [16]. Smaller particles have a greater solubility
than larger ones of the same preparation, due to their
higher surface area and free superficial energy. Spontane-
ous enlargement of colloidal dispersions due to aging, is
accelerated by an increase in precipitate solubility and
may be delayed by diminishing their solubility or by add-
ing very small amounts of tensoactive agents that are ab-
sorbed on the surface of the particle. Taking this into
account, Tween 80 was added to the formulation, but re-
sults were different to those described above because par-
ticle volume showed an increase after kit preparation.
The radiochemical purity of the 188Re-Sn colloid showed
an increase after heating the colloid from thirty to sixty
minutes. This fact implied a slow reaction, which required
this time to reach the best value (95%). Activity distribu-
tion in the different ranges of particle size was not affected
by heating time. Activity absorption on each particle is an
unspecific process. Eighty percent of the activity was kept
in those particles retained by the 5 microns filter – for
heating time of 30, 60 or 90 min-, and these particles were
a small amount of the total preparation. Ninety eight per-
cent of particles, in number, had sizes below 3 microns
and concentrated only about 10% of the whole activity.
This fact confirmed to us that particle volume or surface
area were the main parameters to be taken into account.
Therefore particle size distribution did not correlate with
activity data distribution.
More important changes in particle distribution were de-
tected during the first week after kit preparation, this be-
ing the time needed for colloid stabilization. No further
relevant changes were noted during the stability study so
that eight weeks of shelf life could be safely proposed.
In vivo studies have shown that 48 hours post-administra-
tion knee retention was higher than 90%. One and three
percent of activity was detected in the kidney and liver re-
spectively, which can be attributed to the smallest parti-
cles (less than 1 micron); activities of urine samples were
at background levels.
Figure 8
Selected organ or tissue activity distribution, after 48 hours
intraarticular administration of 188Re-Sn 500 Ci/mL, (18.5
MBq/mL) to New Zealand rabbits (n = 3) in articulation,
heart, kidney, muscle and spleen.
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Figure 9
Scintigraphic images at 0, 24 and 48 hrs after intraarticular
administration of 500 Ci/mL188Re-Sn, (18.5 MBq/mL) to
New Zealand rabbits.BMC Nuclear Medicine 2002, 2 http://www.biomedcentral.com/1471-2385/2/1
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Conclusions
One of the most important characteristics of a radiophar-
maceutical for synovectomy is to deliver a radiation dose
in the target tissue, and if there is any leakage from the
joint this should be insignificant. Good stability and low
cost are also very important features.
The  188Re-Sn colloid fulfilled both objectives, which
makes it an attractive radiotherapeutical agent for rheu-
matoid arthritis treatment in the knee. Forty-eight hours
after administration, nearly 90% of the total radiation re-
mained inside the knee joint.
The 188W/188Re generator, with a shelf life of six months,
had a suitable performance for this clinical application.
The three-dimensional plot representation of colloid
physical characteristics offered valuable information,
both qualitative and quantitative, about colloid particle
behavior. This was very important because particles small-
er than 2 microns, numerically made up more than 90%
of the whole preparation, but the activity remained ad-
sorbed by the bigger ones, which could be retained and/
or phagocyted inside the joint. Distribution by particle
size was the least suitable characterization for detecting
minor differences between the two preparations. If the
membrane filtration method alone had been used for de-
tecting activity distribution on colloid particles, wrong
conclusions might have been reached. The laser diffrac-
tion method allowed us to observe changes in volume or
surface area in colloid particles through time and to deter-
mine slight variations in these parameters.
Physical characterization by laser diffraction was proved
to be a valuable tool for radiopharmaceutical colloid for-
mulations.
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